Business
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
SHANGHAI & CAMBRIDGE, Mass., April 17, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and robust intracranial responses in patients with previously treated extensive stage small cell lung cancer (ES-SCLC) and brain metastases as measured by independent assessment using modified Response Assessment in Neuro-Oncology for Brain Metastases (mRANO-
About this update from Zai Lab Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/adb71eb72292de1c0169287a1bbfe2ab"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JLXcK6zt_Bopn66dHauolQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0OA--/https://media.zenfs.com/en/business-wire.com/adb71eb72292de1c0169287a1bbfe2ab","width":480,"height":224}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases; at 1.6 mg/kg dose, the confirmed iORR was 62.5% (10/16), including complete responses","length":284,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Encouraging activity was observed in extrapulmonary neuroendocrine carcinomas (NECs), with a 38.2% confirmed objective response rate","length":132,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Global Phase 3 trial ongoing in second-line-plus SCLC; first-line SCLC and neuroendocrine carcinoma programs advancing toward registrational phase in 2026","length":154,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Investor conference call and webcast to discuss data being presented at AACR Annual Meeting 2026 and clinical trial plans scheduled for Monday, April 20, at 5:30 a.m. PT / 8:30 a.m. ET / 8:30 p.m. HKT","length":200,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":770,"olType":false},{"type":"text","content":"SHANGHAI & CAMBRIDGE, Mass., April 17, 2026--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and robust intracranial responses in patients with previously treated extensive stage small cell lung cancer (ES-SCLC) and brain metastases as measured by independent assessment using modified Response Assessment in Neuro-Oncology for Brain Metastases (mRANO-BM) criteria, as well as promising data in patients with other neuroendocrine carcinomas (NECs). These findings, as well as preclinical data evaluating ZL-6201 (LRRC15 ADC) and...